<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00885404</url>
  </required_header>
  <id_info>
    <org_study_id>2008/03445</org_study_id>
    <nct_id>NCT00885404</nct_id>
  </id_info>
  <brief_title>Chloride High Level Of Resuscitation Infusion Chloride High Level Of Resuscitation Infusion Delivered Evaluation</brief_title>
  <acronym>CHLORIDE</acronym>
  <official_title>A Prospective, Before and After Study of the Impact of Lower Chloride Intravenous Fluid Management on Patients' Acid-base Status, Renal Profile,Length of Stay and Mortality.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Austin Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Austin Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether intravenous fluid management using lower
      chloride solutions (Hartmann's solutions and Plasmalyte®) will result in better outcome when
      compared to management using high chloride solutions (0.9% saline and Gelofusine®).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, controlled, before-and-after study. The baseline pre-intervention
      period will include collection of data while doctors and nurses are unaware that such
      collection is taking place. During this time, high chloride fluids (saline, Gelofusine, 4%
      albumin) will continue to be used according to standard practice with an estimated 30,000
      liters of saline as well as 2,000 bottles of Gelofusine® being consumed.

      Following a wash out period of education and preparation, there will be a complete shift to a
      working environment where use of saline, Gelofusine and any other fluids with a high chloride
      level (&gt;110 mmol/L)will be restricted and substituted with fluids of lower chloride
      concentration similar to blood; either Hartmann's solution or Plasmalyte® or 20% albumin.

      The study will compare a 6 month control period (before) and a six month intervention period
      (after).
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>February 2009</start_date>
  <completion_date type="Anticipated">August 2010</completion_date>
  <primary_completion_date type="Anticipated">August 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean base excess during hospital stay</measure>
    <time_frame>Six month control period (before) and 6 month intervention period (after)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Unmeasured anions (strong ion gap) and chloride levels during hospital stay</measure>
    <time_frame>Six month control period (before) and 6 month intervention period (after)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum creatine levels</measure>
    <time_frame>Six month control period (before) and 6 month intervention period (after)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of ICU stay</measure>
    <time_frame>Six month control period (before) and 6 month intervention period (after)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Emergency Department stay</measure>
    <time_frame>Six month control period (before) and 6 month intervention period (after)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>Six month control period (before) and 6 month intervention period (after)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-hospital mortality</measure>
    <time_frame>Six month control period (before) and 6 month intervention period (after)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">7000</enrollment>
  <condition>Shock</condition>
  <condition>Critical Illness</condition>
  <arm_group>
    <arm_group_label>Intravenous fluids</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lower chloride fluids (Hartmann's solution and Plasmalyte®)</intervention_name>
    <description>Intravenous fluids used during the 6 month intervention period (after). Amount of fluids to be used is based on clinicians' discretion.</description>
    <arm_group_label>Intravenous fluids</arm_group_label>
    <other_name>Plasmalyte</other_name>
    <other_name>Lactated solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All Intensive Care Unit (ICU) admissions at Austin Hospital

          -  All Emergency Department (ED) admissions at Austin Hospital

          -  All operations at Operating Theatre (OT) with hospital stay of more than 48 hours

        Exclusion Criteria: Nil
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nor'azim Mohd Yunos, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Intensive Care, Austin Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Austin Health</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <reference>
    <citation>Stewart PA. How to understand acid-base. A Quantitative Primer for Biology and Medicine. New York: Elsevier, 1981.</citation>
  </reference>
  <reference>
    <citation>Stewart PA. Modern quantitative acid-base chemistry. Can J Physiol Pharmacol. 1983 Dec;61(12):1444-61.</citation>
    <PMID>6423247</PMID>
  </reference>
  <reference>
    <citation>Sirker AA, Rhodes A, Grounds RM, Bennett ED. Acid-base physiology: the 'traditional' and the 'modern' approaches. Anaesthesia. 2002 Apr;57(4):348-56. Review.</citation>
    <PMID>11939993</PMID>
  </reference>
  <reference>
    <citation>Constable PD. Hyperchloremic acidosis: the classic example of strong ion acidosis. Anesth Analg. 2003 Apr;96(4):919-22. Review.</citation>
    <PMID>12651634</PMID>
  </reference>
  <reference>
    <citation>Dorje P, Adhikary G, McLaren ID, Bogush S. Dilutional acidosis or altered strong ion difference. Anesthesiology. 1997 Oct;87(4):1011-2; author reply 1013-4.</citation>
    <PMID>9357917</PMID>
  </reference>
  <reference>
    <citation>Story DA, Liskaser F, Bellomo R. Saline infusion, acidosis, and the Stewart approach. Anesthesiology. 2000 Feb;92(2):624; author reply 626.</citation>
    <PMID>10691256</PMID>
  </reference>
  <reference>
    <citation>Story DA, Poustie S, Bellomo R. Quantitative physical chemistry analysis of acid-base disorders in critically ill patients. Anaesthesia. 2001 Jun;56(6):530-3.</citation>
    <PMID>11412158</PMID>
  </reference>
  <reference>
    <citation>Reid F, Lobo DN, Williams RN, Rowlands BJ, Allison SP. (Ab)normal saline and physiological Hartmann's solution: a randomized double-blind crossover study. Clin Sci (Lond). 2003 Jan;104(1):17-24.</citation>
    <PMID>12519083</PMID>
  </reference>
  <reference>
    <citation>Dorje P, Adhikary G, Tempe DK. Avoiding latrogenic hyperchloremic acidosis--call for a new crystalloid fluid. Anesthesiology. 2000 Feb;92(2):625-6.</citation>
    <PMID>10691258</PMID>
  </reference>
  <reference>
    <citation>Morgan TJ, Venkatesh B, Hall J. Crystalloid strong ion difference determines metabolic acid-base change during in vitro hemodilution. Crit Care Med. 2002 Jan;30(1):157-60.</citation>
    <PMID>11902256</PMID>
  </reference>
  <reference>
    <citation>Kellum JA. Fluid resuscitation and hyperchloremic acidosis in experimental sepsis: improved short-term survival and acid-base balance with Hextend compared with saline. Crit Care Med. 2002 Feb;30(2):300-5.</citation>
    <PMID>11889298</PMID>
  </reference>
  <reference>
    <citation>Morgan TJ, Venkatesh B, Hall J. Crystalloid strong ion difference determines metabolic acid-base change during acute normovolaemic haemodilution. Intensive Care Med. 2004 Jul;30(7):1432-7. Epub 2004 Feb 28.</citation>
    <PMID>14991093</PMID>
  </reference>
  <reference>
    <citation>Story DA, Morimatsu H, Bellomo R. Hyperchloremic acidosis in the critically ill: one of the strong-ion acidoses? Anesth Analg. 2006 Jul;103(1):144-8, table of contents.</citation>
    <PMID>16790643</PMID>
  </reference>
  <verification_date>February 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 21, 2009</study_first_submitted>
  <study_first_submitted_qc>April 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2009</study_first_posted>
  <last_update_submitted>February 24, 2010</last_update_submitted>
  <last_update_submitted_qc>February 24, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 25, 2010</last_update_posted>
  <responsible_party>
    <name_title>Nor'azim Mohd Yunos</name_title>
    <organization>Clinical Research Fellow, Department of Intensive Care, Austin Hospital.</organization>
  </responsible_party>
  <keyword>chloride</keyword>
  <keyword>acidosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Plasma-lyte 148</mesh_term>
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

